COMPARISON OF KRAS TESTED AND NOT-TESTED METASTATIC COLORECTAL CANCER (MCRC) PATIENT COHORTS IN EUROPE
Author(s)
Narayanan S1, Gallo F2
1Ipsos Healthcare, Washington, DC, USA, 2Ipsos Healthcare, New York, NY, USA
Presentation Documents
OBJECTIVES: Compare the characteristics of mCRC patients either tested or not for KRAS mutations in Europe in 2009 and 2013. METHODS: A multi-country retrospective medical chart-review of mCRC patients were conducted by cancer treating physicians in Germany/France/Spain/Italy (EU4) and the UK; Data collection period was 2009-2013. Physicians were recruited from a geographically representative sample in each country. Approximately 10-25 eligible patients on usual care anti-cancer regimen were identified by each physician within each of the four-quarterly study observation-windows in respective years. Physicians abstracted data on patient demographics, disease status, treatment patterns and biomarker status .The analysis focused on patients that were either tested (T) or not (NT) for KRAS mutation in 2009 and 2013. RESULTS: Approximately 2350 mCRC patient-charts (UK~300/EU4~2050) were abstracted in both 2013 and 2009. Proportion of patients who were male in 2013 were: T-62%/NT-60% in both UK and EU4; a directional shift towards more male patients in UK and towards more female patients in EU4 was noted from 2009 to 2013. Mean age was: T-55yrs/NT-66yrs in UK and T-64yrs/NT-66yrs in EU4 in 2009, while T-67yrs/NT-68yrs in UK and T-66yrs/NT-72yrs on EU4 in 2013. Majority (UK:56%/EU4:47%) of KRASm-tested patients were follow-up patients in 2009 while the majority (UK:57%/EU4:42%) had relapse-status in 2013. Proportion of patients with an ECOG score of >=1 at the time of visit was: T-68%/NT-77% in UK, T-60%/NT-66% in EU4 in 2009; T-82%/NT-76% in UK, T-74%/NT-79% in EU4 in 2013. CONCLUSIONS: Distinct differences appear to exist within mCRC cohorts based on the KRASm test status (T/NT), geography (UK/EU4) and the observation time-span (2009/2013). This warrants further research to understand the drivers behind the observed patterns and to facilitate optimal care deliverythat could eventually lead to the utilization of targeted oncology therapeutics to alleviate patient burden and improve outcomes.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PMD119
Topic
Health Policy & Regulatory, Health Service Delivery & Process of Care
Topic Subcategory
Pricing Policy & Schemes, Treatment Patterns and Guidelines
Disease
Oncology